logo
Share SHARE
FONT-SIZE Plus   Neg

New Data On Novartis' Lucentis Confirms Benefits Of Individualized Treatment

Novartis AG (NVS) said new data for Lucentis (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections.

In addition, Lucentis exhibited benefits in visual acuity outcomes in patients with visual impairment due to choroidal neovascularization secondary to pathological myopia. At present, Lucentis is not approved to treat this condition. Novartis noted that it will submit for regulatory approval in this indication in the European Union in the third quarter of this year and in Japan by late 2012.

Tim Wright, Global Head of Development, Novartis Pharma, commented, "Lucentis has become the standard of care in wet AMD and has helped to significantly improve vision in a majority of patients with this disease. These new data confirm that an individualized treatment approach can lead to optimal improvements in vision with a low average number of treatments, thus ensuring that patients with retinal diseases are not over- or under-treated. In addition, these data add to the well-characterized safety profile of Lucentis."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Canada based Maple Leaf Foods Inc. Wednesday said it has reached a definitive agreement with Brynwood Partner VI L.P. for the acquisition of Lightlife Foods Inc. The deal would be worth $140 million plus other costs. Light is a brand in U.S. for refrigerated plant based protein foods. A hedge fund is an alternative investment fund that uses pooled funds from accredited individuals or institutional investors and invests these funds in different assets with a goal of generating high returns. Hedge funds are generally accessible only to accredited or qualified investors. They cannot... Off-price retailer TJX Companies, Inc. reported a nearly 2 percent increase in profit for the fourth quarter from last year, reflecting higher sales and customer traffic. Both revenue and earnings per share for the quarter beat analysts' expectations. The company forecast earnings for the first quarter below the Street estimates and projects fiscal 2018 earnings above their expectations.
comments powered by Disqus
Follow RTT